Ultrasound applications in the treatment of major depressive disorder (MDD): A systematic review of techniques and efficacy in clinical trials and animal model studies

Gansheng Tan[1,2], Hong Chen[1,2], Eric C. Leuthardt[1,2,3]
[1]Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA
[2]Department of Neurosurgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
3Department of Neuroscience, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA

Short title: Ultrasound treatment of depression

Corresponding author:
Eric C. Leuthardt MD
Department of Neurosurgery
Washington University School of Medicine
Campus Box 8111
660 South Euclid Avenue
St. Louis, MO 63110
Email: leuthardte@wustl.edu

Abstract

Objective

Major depressive disorder (MDD) is a debilitating condition that inflicts significant personal and economic burdens and affects around 8% of the US population. Approximately 30% of patients with MDD do not respond to conventional antidepressant and psychotherapeutic treatments. Current treatment options for refractory MDD include transcranial magnetic stimulation (TMS) and invasive surgical procedures such as surgical ablation, vagus nerve stimulation, and deep brain stimulation. While TMS is noninvasive, its clinical efficacy remains modest. Surgical interventions carry significant risks and are associated with low patient acceptance due to their invasive nature. In this context, therapeutic ultrasound emerges as a promising alternative for treating refractory MDD, which has the unique advantage of combining non-invasiveness with selective targeting. Over the past 10 years, there has been a growth in focused ultrasound research, leading to an exponential increase in interest in the technology. To support the future development of ultrasound for treating MDD, we conducted a systematic review following Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines.

Materials and Methods

We identified 70 relevant studies. Our inclusion criteria were peer-reviewed prospective cohort studies, case-control studies, and randomized controlled trials that report ultrasound efficacy for treating depression in humans or depressive-like behaviors in animal models (PROSPERO registration number: CRD42024626093). Nineteen studies met all inclusion criteria. We summarized ultrasonic techniques for treating depression and their efficacy.

Results

Two focused ultrasound (FUS) techniques used to treat depression include magnetic resonance-guided focused ultrasound (MRgFUS) for capsulotomy and low-intensity focused ultrasound (LIFUS) neuromodulation. In human trials, the response rate (≥50% improvement in depression score from baseline) for MRgFUS capsulotomy and LIFUS neuromodulation were 53.85% and 77.36%, respectively. In addition, LIFUS neuromodulation had a medium-to-large effect (|Cohen's d| > 0.6) on reducing standard depression scale scores or resolving depressive-like behaviors in rodents. The certainty of evidence is moderate for human trials and low for rodent models. MRgFUS capsulotomy had inconsistent lesioning success and a limited response rate, while LIFUS neuromodulation lacked systematic exploration of the parameter space and clear delineation of the underlying mechanisms. Future work should refine patient selection for MRgFUS capsulotomy and optimize the parameters for individualized functional targeting.

Conclusions

LIFUS neuromodulation achieved a medium-to-large reduction in depressive behaviors in both rodent models and human trials. We conclude that LIFUS neuromodulation is a promising, noninvasive option for treating refractory MDD.

Introduction

Major depressive disorder (MDD) is a severe form of mood disorder characterized by prolonged sadness, fatigue, cognitive impairments, and, in severe cases, suicidal thoughts or behaviors. An estimated 21 million adults in the United States (8.3% of all adults) had at least one major depressive episode in 2021[1]. The biological mechanisms underlying MDD are multifactorial, including dysregulation of monoaminergic neurotransmitter systems, hypothalamic–pituitary–adrenal axis dysfunction, elevated inflammatory cytokines, genetic predispositions, structural and functional brain changes, and sociopsychological events[2–5]. The serotonin theory of depression posits that reduced serotonin activity contributes to depressive symptoms[6]. This theory arose in 1990, which has promoted the use of antidepressants, particularly selective serotonin reuptake inhibitors, as standard treatments for MDD. However, a large-scale trial showed that nearly 80% of the outpatients treated with antidepressants had chronic or recurrent major depression[7], and approximately 30% of patients with refractory MDD resists further treatments after failed treatment attempts[8]. For these patients, invasive neurosurgical procedures such as bilateral anterior capsulotomy, bilateral anterior cingulotomy, vagus nerve stimulation, and deep brain stimulation are sometimes pursued. These surgical approaches aim to disrupt the aberrant brain networks implicated in MDD, but yield mixed clinical results and carry risks of intracranial hemorrhage, delayed edema, or brain cyst formation[9,10]. The US Food and Drug Administration (FDA) approved the use of transcranial magnetic stimulation (TMS) for MDD in 2008. Although TMS is non-invasive, its clinical efficacy has been modest (29.3% response rate)[11]. The standard TMS treatment protocol typically requires daily sessions over several weeks, which can hinder patient adherence.

In recent years, there has been increasing interest in using ultrasound for treating depression largely because it can reach deeper brain targets implicated in MDD and can be precisely focused to target specific brain regions, distinguishing focused ultrasound (FUS) stimulation from other non-invasive modalities, such as transcranial direct/alternating current stimulation and TMS. Ultrasound technology can be categorized into diagnostic ultrasound and therapeutic ultrasound. Therapeutic ultrasound directs the ultrasound (i.e., mechanical waves with frequencies greater than 20 kHz) to the target through FUS transducers. Effective ultrasound transmission requires a coupling medium (e.g., ultrasound gel) to be applied between the transducer and tissue because absorption and reflection occur at interfaces between materials of different acoustic impedance. The therapeutic effects of ultrasound are primarily mediated by the thermal and mechanical effects. One form of therapeutic ultrasound is high-intensity focused ultrasound (HIFUS), which is mostly used for tissue ablation. It achieves ablation either by inducing coagulative thermal necrosis due to the absorption of ultrasound energy or by causing mechanical ablation through high-tensile pressure-induced cavitation[12]. In contrast, low-intensity focused ultrasound (LIFUS) has been proven to modulate neuronal activity without causing irreversible damage. While the exact mechanism mediating LIFUS neuromodulation remains unclear, it is thought to involve acoustic radiation force, cavitation

effect (oscillation of gas bubbles within tissues), and thermal effect (for a review of the mechanism, see[13]).. Preclinical studies showed that LIFUS neuromodulation in animal models improved depressive-like behaviors[14–20]. A few clinical trials in the past five years explored the use of ultrasound for thermal ablation and neuromodulation as treatment for major depressive disorders[21–23]. Despite great progress, therapeutic ultrasound has not been widely adopted for treating MDD. To establish the therapeutic potential of FUS in treating MDD, we conducted a systematic review of studies applying ultrasound to treat depression (clinical trials) and depression-like behaviors (animal models), and comparatively evaluated the reported efficacies. This review discusses the challenges of developing ultrasound to treat MDD and proposes directions for future research.

Materials and Methods

Systematic review design

This systematic review was preregistered in PROSPERO (CRD42024626093) and follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines[24] (**Fig 1**). We originally planned to limit the review to human studies. We expanded the original protocol to include both human studies and animal model studies due to the limited number of clinical trials evaluating ultrasound applications in treating MDD.

Search strategy

We conducted a systematic literature search using PubMed and Web of Science. The last search was conducted on December 10, 2024. We searched peer-reviewed papers that contain the keyword *Ultrasound* in the title AND the keywords *Ultrasound*, *neuromodulation*, *treatment*, and *depression* in all fields. Individual additional articles known to the authors were also added. The inclusion criteria: (1) published in English, (2) used ultrasound-based technology for treating depression.

Eligibility criteria

The selected studies included human subjects diagnosed with MDD or animal models exhibiting depression-like behaviors. We included prospective cohort studies, case-control studies, and randomized control trials that reported the effects of ultrasound treatment on MDD or depression-like behaviors. We included studies with full-text in English that evaluate the effect of any form of ultrasound application on depression, including but not limited to low-intensity focused ultrasound (LIFUS), high-intensity focused ultrasound (HIFUS), or ultrasound-guided interventions. The selected studies report clinical and functional outcomes such as the Hamilton Depression Rating Scale, neuroimaging outcome, electrophysiological outcome or and biochemical analyses.

Study selection

One reviewer removed duplicate reports (n = 16) before the study selection. Thus, a total of 54 articles (*n*=51 articles retrieved from databases and *n*=3 additional articles) were included in the study selection screen. We assessed the eligibility of each retrieved study in two phases (1) a screen of title and abstract, and (2) a full-text review. The first reviewer sent the assessment of eligibility to the second reviewer and any disagreements in the study selection were thoroughly discussed. The third reviewer made a final decision about study eligibility if the first and second reviewers did not reach consensus. For cases of multiple studies reporting results from the same trial, we focused on the outcomes reported in the study that analyzed a larger sample. Application of all selection and exclusion criteria removed 35 articles, which left 19 articles that were subjected to data extraction and statistical analyses.



Fig 1. PRISMA flow diagram for study identification and selection.

Quality assessment

To ensure a rigorous evaluation of the included studies, we assessed risk of bias and methodological quality using standardized tools appropriate to the study design. Specifically, we applied RoB 2 for randomized controlled trials, ROBINS-E for open-label clinical studies, and SYRCLE's risk of bias tool for preclinical animal studies[25–27]. To provide a uniform framework for quality assessment, we adapted standardized tools and assessed each of the 19 included studies for risk of bias based on three categories: selection, comparability, and outcome. The maximum score for each category is 1. Good studies were defined as those that scored 1 in one category and at least 0.5 in the other two categories. Poor studies were defined as those that scored 0 in any one of the three categories. We consider the rest of the studies of moderate quality. All reviewers discussed and resolved any disagreements on quality assessment.

Data extraction

For human studies, we extracted the mean and variance of standard depression scales, including the Hamilton Depression Rating Scale and the Montgomery-Åsberg Depression Rating Scale, at baseline and the latest follow-ups. We also extracted the number of responders. For animal model studies, we extracted the mean and variance of measures for depressive-like behavior, including immobility time in the forced swim test and the tail suspension test, and the sucrose preference index in the sucrose preference test. For all included studies, we extracted the sample size and the reported adverse effects. For studies that reported results for both per-protocol samples and intent-to-treat samples, we prioritized extracting statistics from the intent-to-treat samples when available.

Statistical analysis

We retrieved or inferred the effect size (e.g., Cohen's d) between the ultrasound treatment and control groups or between baseline and follow-up data. When available, we extracted means, variances [e.g., standard errors (SE) or standard deviation (SD)], and sample sizes to estimate the effect size d and its variance $Var(d)$ (Eqs. 1-3). In studies that conducted Analysis of Variance (ANOVA) and reported F-statistics and degrees of freedom for the treatment effect df_{effect} and residual degrees of freedom df_{error}, we estimated effect sizes and variances based on Eqs. 3-6[28]. For studies where means and variances were not reported but t-statistics were available, we calculated the effect size d and its variance $Var(d)$ using Eqs. 3 and 7. We estimated the overall effect size using fixed-effect models with inverse variance as the weighting method. We estimated pooled effect size $\bar{d}$ according to Eq. 8. We estimated the 95% confidence interval (CI) as $\bar{d} \pm 1.96 \cdot SE$ (Eq. 9). We evaluated heterogeneity across studies by calculating the I^2 metric[29]. A study of low-intensity pulsed ultrasound in a rat model of chronic stress tested three pulse frequencies (200, 285, and 500 Hz) and reported a significant effect only at 200 Hz[17]. Due to non-significant effects at 285 Hz or 500 Hz and the lack of exact statistics for these frequencies, we assumed their effect sizes to be zero and synthesized the results to estimate the overall effect before pooling data across studies. In human studies, we adhered to the definition of responder as a 50% reduction in the standard

depression scale value[9]. We synthesized the number of responders and total subjects across studies to calculate the overall response rate. For human randomized trials that reported depression scale at baseline and after the treatment for both active and sham treatment groups, we estimated the effect size of ultrasound treatment and the effect size of ultrasound treatment compared with sham treatment, both adjusted for baseline. We defined the overall effect size large for $\bar{d} > 0.8$, medium for $0.2 \leq \bar{d} \leq 0.5$, and small for $\bar{d} < 0.2$.

$$d = \frac{Mean_{ultrasound\ treatment} - Mean_{control}}{Pooled\ SD} \quad \text{Eq. 1}$$

$$Pooled\ SD = \sqrt{\frac{(n_{control} - 1) \cdot SD_{control} + (n_{ultrasound\ treatment} - 1) \cdot SD_{ultrasound\ treatment}}{n_{control} + n_{ultrasound\ treatment} - 2}} \quad \text{Eq. 2}$$

$$Var(d) = \frac{n_{ultrasound\ treatment} + n_{control}}{n_{ultrasound\ treatment} \cdot n_{control}} + \frac{d^2}{2 \cdot (n_{ultrasound\ treatment} + n_{control})} \quad \text{Eq. 3}$$

$$\eta^2 = \frac{F \cdot df_{effect}}{F \cdot df_{effect} + df_{error}} \quad \text{Eq. 4}$$

$$Cohen's\ f = \sqrt{\frac{\eta^2}{1 - \eta^2}} \quad \text{Eq. 5}$$

$$d = \begin{cases} 2 \cdot Cohen's\ f & if\ number\ of\ groups = 2 \\ 2 \cdot Cohen's\ f \sqrt{\frac{number\ of\ groups}{number\ of\ groups - 1}} & if\ number\ of\ groups > 2 \end{cases} \quad \text{Eq. 6}$$

$$d = \frac{t}{\sqrt{n_{ultrasound\ treatment} + n_{control}}} \quad \text{Eq. 7}$$

$$\bar{d} = \frac{\sum \frac{1}{Var(d_i)} \cdot d_i}{\sum \frac{1}{Var(d_i)}} \quad \text{Eq. 8}$$

$$SE = \frac{1}{\sum \frac{1}{Var(d_i)}} \quad \text{Eq. 9}$$



Fig 2. Summary of techniques, targets, and potential mechanisms in the application of high-intensity focused ultrasound (HIFUS) thermal ablation and low-intensity focused ultrasound (LIFUS) neuromodulation for treating depression. **A**. Ultrasonic applications can be categorized into LIFUS or HIFUS based on the intensity (e.g., acoustic pressure). Each category involves distinct techniques and mechanisms. **B**. HIFUS was primarily used for thermal ablation in humans. MR: magnetic resonance. **C**. LIFUS neuromodulation involves five independent parameters: fundamental frequency, pulse repetition frequency, tone burst duration, inter-stimulus interval, and sonication duration. Techniques for applying LIFUS include single Magnetic Resonance Imaging (MRI)-calibrated LIFUS[30,31] and Neuronavigation-guided LIFUS[22]. Single MRI-calibrated LIFUS involves mechanically registering the device to the subject's head and calibrating the beamforming based on a single MR scan. Neuronavigation-guided LIFUS maps the stimulation target in the physical space using imaging data and fiducial markers. Real-time infrared tracking enables the alignment of the FUS transducer to the target. VTA: ventral tegmental area. The primary mechanisms mediating LIFUS are thought to be radiation force (membrane deformation and mechanosensitive ion channel activation caused by ultrasound) and thermal effects.

Results

This review analyzes data from 19 peer-reviewed articles investigating ultrasound applications in the treatment of depression or depression-like behaviors (**Table 1**). The 19 peer-reviewed articles comprise 11 human studies and 8 studies using animal models. The 11 human studies report results from five trials, including four registered clinical trials (NCT02348411, NCT05301036, NCT04405791, and NCT03421574). The 8 animal studies used mice and rats, and four of these used restraint stress models. The rodent models in the remaining four studies include chronic corticosterone-induced depressive-like behaviors, chronic unpredictable stress, Lipopolysaccharide-induced depressive-like behaviors, and 6 hydroxydopamine (6-OHDA) lesion-induced anhedonic-like behaviors. For the latest reports of three independent randomized controlled trials investigating LIFUS neuromodulation, the ROB2 assessment indicated a low to moderate risk of bias (see **source data – ROB2 assessment** for details). ROBINS-E for open-label human studies identified some concerns for risk of bias, primarily arising from measurement of the outcome as participants and investigators were aware of the intervention (see **source data – ROBINS-E Tool** for details). For preclinical studies, SYRCLE's risk of bias tool identified that most animal studies had risk of bias related to group allocation and blinding, as many did not explicitly stated whether allocation was concealed from the investigators or whether outcome assessors were blinded (see **source data – animal SYRCLE's risk of bias** for details). The adapted quality evaluation of the 19 studies indicated that 12 are of good quality, 4 are of moderate quality, and 3 are of poor quality (**Supplementary Fig 1**.)

Table 1 Summaries of methods, outcomes, and efficacies reported in the included studies.

Source	Protocol	Relevant outcomes	Efficacy	Additional findings
Preclinical studies (rodent models)				
Wu et al.[15], 2023	Transcranial ultrasound stimulation (TUS) targeting dorsal raphe nucleus with 1.1 MHz fundamental frequency, 1000 Hz pulsed repetition frequency, 0.5 ms tone burst duration (TBD), 1 s stimulation duration (SD), 1 s inter-stimulus interval (ISI).	c-Fos immunoreactivity, sucrose preference index, immobility time in tail suspension test, time spent in elevated plus-maze test, levels of serotonin	Mice receiving TUS exhibited improved depression-like behaviors compared to the control group.	Staining showed no damage in the dorsal raphe nucleus tissue.
Hou et al.[16], 2024	Low-frequency, low-intensity ultrasound combined with stereotactic injections of nanobubbles (PEGylated gas vesicles) targeting dorsal raphe nucleus with 1 MHz frequency, 1000 Hz pulsed repetition frequency, and 0.3 ms tone burst duration.	Immobility time in forced swim test and tail suspension test.	Mice receiving ultrasound neuromodulation exhibited reduced immobility time.	Ultrasound induced a 2.5-fold increased expression of c-Fos in 5-HT neurons compared to the control condition

Source	Protocol	Relevant outcomes	Efficacy	Additional findings
Zhang et al.[17], 2021	Low-intensity pulsed ultrasound targeting ventromedial prefrontal cortex with 800 kHz frequency, 200 Hz pulsed repetition frequency, 1 s sonication duration, 3 s inter-stimulus interval, and 0.2 ms tone burst duration.	Immobility time in the forced swimming test, sucrose preference index in sucrose preference test, distance traveled in open field test, and c-Fos immunoreactivity	Four weeks of ultrasound stimulation targeting ventromedial prefrontal cortex increased sucrose preference, reduced forced swim immobility time in stressed rats, but had no significant effect on distance traveled in open field test.	Number of c-Fos-positive cells in the ventromedial prefrontal cortex was significantly increased. Histological staining revealed no gross tissue damage.
Yi et al.[18], 2022	Low-intensity pulsed ultrasound targeting ventromedial prefrontal cortex with 500 kHz fundamental frequency, 100 Hz pulsed repetition frequency, 60 s sonication duration, 120 s inter-stimulus interval, and 5 ms tone burst duration.	c-Fos immunoreactivity in prefrontal neuron, immobility time in forced swimming test, immobility time in tail suspension test.	Ultrasound stimulation increased the expression of c-Fos and reduced immobility time.	Ultrasound stimulation did not cause any damage in prefrontal cortex based on H&E and Nissl staining.
Zhu et al.[19], 2023	Transcranial low-intensity (pulsed) ultrasound stimulation targeting the dorsal raphe nucleus with 1.1 MHz frequency, 1000 Hz pulsed repetition frequency, 1 s sonication duration, 1 s inter-stimulus interval, and 0.5 ms tone burst duration.	c-Fos immunofluorescence, sucrose preference index in sucrose preference test, immobility time in tail suspension test	Three weeks of stimulation significantly reduced immobility time compared with the non-stimulated group. c-Fos positive cells expression levels and the 5-HT levels in the dorsal raphe nucleus increased after stimulation.	H&E staining did not reveal tissue damage
Zhang et al.[20], 2018	Transcranial (pulsed) ultrasound stimulation targeting the prelimbic cortex with 500 kHz fundamental frequency, 1.5 kHz pulsed repetition frequency, 0.4 s sonication duration, 3 s inter-stimulus interval, and 0.4 ms tone burst duration.	Sucrose preference index in sucrose preference test, immobility time in forced swimming test, distance travelled in open field test, brain-derived neurotrophic factor in left hippocampus	Two weeks of LIFUS stimulation led to higher sucrose preference index, increased distance traveled, and reduced immobility time.	H&E staining confirmed no tissue damage or hemorrhage after sonication.
Herlihy et al.[32], 2023	Peripheral (pulsed) ultrasound stimulation targeting the celiac plexus with 2.5 MHz fundamental frequency, 5 Hz pulsed repetition frequency, and 0.25 ms tone burst duration.	Immobility time in forced swim test, sucrose preference index in sucrose preference test	Ultrasound stimulation increased sucrose preference in hemiparkinsonian rats.	N/A
Wang et al.[14], 2024	Transcranial ultrasound stimulation targeting the ventral tegmental area with 0.5 MHz fundamental frequency, 1.5 Hz pulsed repetition frequency, 0.3 ms tone burst duration, 0.2 s sonication duration, and 1.6 s inter-stimulus interval	Immobility time in forced swimming test, immobility time in tail suspension test, sucrose preference index in sucrose preference test, dopaminergic release in prefrontal cortex based on fiber photometry, and the	Ultrasound stimulation improved depression-like behavior and increased dopamine levels in prefrontal cortex.	N/A

Source	Protocol	Relevant outcomes	Efficacy	Additional findings
		number of dopaminergic neuron in ventral tegmental area.		
Human studies				
Davidson et al.[33], 2021	Magnetic resonance imaging (MRI)-guided focused ultrasound for bilateral capsulotomy	Treatment success ratio defined by visible bilateral lesions on postoperative MRI.	Clinical response was reported in Ref[9]	The treatment success ratio was 15/22
Hamani et al.[23], 2024	Magnetic resonance (MR)-guided focused ultrasound for anterior capsulotomy	Clinical evaluation for adverse effects, Hamilton Depression Rating Scale scores	Non-significant reduction in Hamilton Depression Rating Scale scores compared to baseline in patients with major depressive disorder.	No serious adverse effects were reported.
Davidson et al.[34]. 2020	MR-guided focused ultrasound for anterior capsulotomy.	Functional connectivity based on functional MRI, cerebral glucose metabolism based on positron emission tomography,	Updated clinical efficacy and safety evaluation were reported in Ref[23].	No cognitive decline was reported
Davidson et al.[9], 2020	Magnetic resonance-guided focused ultrasound for anterior capsulotomy	Neuropsychological tests	Improvements in clinical symptoms correlated with improvements in self-reported measures of executive dysfunction and disinhibition, but not with performance-based tasks. Updated clinical efficacy and safety evaluation were reported in Ref[23].	No serious adverse effects were reported after the procedure. Nonserious adverse events included headaches and pin-site swelling in 7/12 patients.
Oh et al.[22], 2024	Imaging-guided transcranial FUS targeting left dorsal lateral prefrontal cortex with 250 kHz fundamental frequency, 500 Hz pulsed repetition frequency, 1 ms tone burst duration, 0.3 s sonication duration, 5.7 s inter-stimulus interval.	Montgomery-Åsberg Depression Rating Scale and Resting-state functional magnetic resonance imaging	Ultrasound stimulation reduced Montgomery-Åsberg Depression Rating Scale and increased connectivity between subgenual anterior cingulate cortex and prefrontal cortex.	N/A
Riis et al.[30], 2024	Transcranial FUS targeting the subgenual cingulate cortex with 650 kHz fundamental	Depression and anxiety rating.	Ultrasound stimulation improved mood states.	No adverse effect or apparent changes in structural imaging were reported. Targeting accuracy was on a scale of millimeter.
Kim et al.[21], 2018	MR-guided focused ultrasound for anterior capsulotomy	Hamilton Depression Rating Scale score and Beck Depression Inventory score	The procedure improved objective depression scale scores	N/A
Riis et al.[31], 2023	Transcranial FUS targeting the subgenual cingulate cortex and pregenual cingulate with 650 kHz	Hamilton Depression Rating Scale score	Ultrasound stimulation decreased Hamilton Depression Rating Scale	No adverse effects were reported.

Source	Protocol	Relevant outcomes	Efficacy	Additional findings
	fundamental frequency for 2 minutes and 30 ms sonication duration, and 4 s inter-stimulus interval.		score, which remained low for 44 days following the sonication.	
Davidson et al.[35], 2020	MR-guided focused ultrasound for bilateral capsulotomy	The number of sonification and acoustic energy required for each side	Clinical response was reported in Ref[9]	Greater acoustic energy is needed for treatment of the second side.
Xu et al.[36], 2020	A combination of transcranial magnetic stimulation and MRI-guided low-intensity focused ultrasound stimulation, targeting lateral orbitofrontal cortex, dorsal prefrontal cortex, and cuneiform lobe with 650 kHz fundamental frequency, 100 Hz pulse repetition frequence, 30 s sonication duration, 30 s inter-stimulus interval.	Hamilton Depression Rating Scale score	Hamilton Depression Rating Scale score was lower in the treatment group than in the control group.	No statistical difference in adverse reactions between the treatment and control groups.
Riis et al.[37], 2024	MRI-guided LIFUS targeting bilateral subcallosal cingulate cortex with 650 kHz fundamental frequency, 200 Hz pulsed repetition frequency, 1 MPa amplitude (31.1 W/cm), 30 ms sonication duration, and 1.4 s inter-stimulus interval.	Sadness subscale of the expanded Positive and Negative Affect Schedule (PANAS-X), Hamilton Depression Rating Scale score-6 (HDRS-6), blood oxygenation level–dependent (BOLD) signal.	In the per-protocol sample, active stimulation group had greater reduction in the PANAS-X score immediately following treatment, and greater reduction in HDRS-6 scores at 24s hour, but not at 7 days.	Functional MRI shows deactivation in the subcallosal cingulate cortex, and activation in the left ventrolateral prefrontal cortex and bilateral temporal cortex. No severe adverse events occurred during or immediately after stimulation. Two subjects in the active stimulation group experienced a severe psychiatric adverse event 24-hour after treatment.

HIFUS thermal ablation to treat depression

Both LIFUS and HIFUS have been used to treat human patients with major depressive orders (**Figure 2A**). HIFUS was applied to ablate the anterior limb of the internal capsule in patients with MDD. This technique, called magnetic resonance-guided focused ultrasound (MRgFUS), directs ultrasound to generate heat at the target site and cause coagulative necrosis and tissue ablation (**Figure 2B**). MRgFUS creates intracranial lesions without requiring a cranial window through craniotomy. The US Food and Drug Administration (FDA) approved MRgFUS for the treatment of refractory essential tremor in July 2016. Subsequently, MRgFUS has been investigated as a non-invasive ablation method for other neurological disorders, including MDD, Obsessive-compulsive disorder, and brain tumors[38]. In human studies included in this review, eligible patients for MRgFUS are those with treatment-resistant MDD. These studies utilized MRgFUS to target the anterior limb of the internal capsule, a white matter region that contains fibers from the prefrontal cortex towards the ventral striatum and the

thalamus. The therapeutic mechanism mediating MRgFUS capsulotomy involves the disruption of the output from the anterior nucleus of the thalamus projecting to the paraterminal gyrus tract while preserving the dorsolateral prefrontal-thalamic tracts to avoid causing frontal lobe syndrome. The MRgFUS procedure is administered as follows. Patients are positioned in an intraoperative MRI scanner with a stereotactic frame, and test sonication is performed for target validation and adjustment and HIFUS for ablation. low-energy sonication pulses are delivered to induce temperatures of 40°–42°C, which serves to verify targeting accuracy before applying HIFUS. Temperature feedback from MR thermometry allows the neurosurgical team to make millimeter-scale adjustments to ensure that the focal point of heating aligns with the intended target region. Following successful verification, high-power sonication pulses are applied iteratively, raising temperatures to between 50–56°C for durations exceeding three seconds.

LIFUS neuromodulation to treat depression

In contrast to HIFUS, LIFUS is used to modulate neuronal activity without creating irreversible lesions. MDD is associated with dysregulation of neurotransmitter systems and neural circuits involved in mood regulation, stress response, and reward processing. LIFUS is gaining attention as a non-invasiveness neuromodulation technique with high spatial resolution and deep penetration depth for treating patients with drug-resistant MDD. Preclinical studies with depressive rodent models administer LIFUS via transcranial low-intensity pulsed ultrasound stimulation, which reduces the risk of thermal damage at the targeted brain region compared to continuous wave ultrasound. In these studies, the targeted brain regions include the dorsal raphe nucleus, prefrontal cortex, and ventral tegmental area. Three out of eight animal studies included in this review targeted the dorsal raphe nucleus to facilitate serotonin release[15,16,19], while another three targeted the prefrontal cortex for its role in emotion regulation[17,18,20]. One study directed LIFUS toward the ventral tegmental area to regulate the dopamine system[14]. Beyond central targets, one study stimulated the vagus nerve by targeting the celiac plexus to harness the antidepressant effects of the vagus nerve stimulation[32]. One out of eight included rodent studies uniquely combined transcranial low-intensity ultrasound with PEGylated gas vesicles.

LIFUS neuromodulation protocol involves five independent parameters (**Figure 2C**): fundamental frequency, pulse repetition frequency, tone burst duration, inter-stimulus interval, and sonication duration. The fundamental frequency determines the oscillation rate of the ultrasound waves, which influences penetration depth. Pulse repetition frequency is the rate at which ultrasound pulses are emitted. The tone burst duration is the length of each ultrasound pulse, and inter-stimulus interval is the time between consecutive pulses. Higher pulse repetition frequencies combined with longer sonication duration and shorter inter-stimulus interval may increase the risk of tissue heating. Transcranial low-intensity pulsed ultrasound has been applied in animal studies using a broad range of parameters: fundamental frequency ranging from 0.5–2.5 MHz, pulse repetition frequency ranging

from 5–1.5 kHz, tone burst duration ranging from 0.2–5 ms, sonication duration ranging from 0.2–120 s, and inter-stimulus interval ranging from 1–120 s (**Table 1**).

Human trials are beginning to explore the use of transcranial low-intensity pulsed ultrasound stimulation to treat patients with MDD[22,30,31,36]. These trials have used neuroimaging or optical tracking-based neuronavigation as guidance to target specific brain regions implicated in depression. There are currently two types of protocols: the patient's head is immobilized with thermoplastic masks and mechanically coregistered with ultrasound transducers, or the patient's head is allowed to move. For the head immobilization protocol, MRI is utilized to map the patient's brain anatomy in relation to fiducial markers affixed to the transducers. Based on the brain anatomy, transducer locations, and acoustic pressure mapping, the ultrasound can be steered to focus on the targeted brain area. For the protocol that allows head motion, fiducial points are affixed to the patient's head and the transducers. Real-time tracking with an infrared camera enables positioning of the ultrasound transducer with respect to the fiducial points on the patient's head and the transducers. The brain regions that were targeted with low-intensity pulsed ultrasound stimulation include the sub- and pre-genual anterior cingulate cortex, dorsal prefrontal cortex, lateral orbitofrontal cortex, and cuneiform lobe. The treatment protocol varied from study to study, with fundamental frequency ranges from 250–650 kHz and treatment protocol lasting from minutes to weeks (**Table 1**). The LIFUS protocols reported in the included human trials included in this review administered low-intensity pulsed stimulation without administering microbubbles. These protocols are expected to have a low likelihood of inducing cavitation effects; therefore, we do not highlight cavitation effects in **Figure 2C**.

Efficacy of HIFUS thermal ablation for treating depression

Our analysis of six studies in humans reporting the results of three clinical trials (NCT02348411, NCT03421574, and NCT03156335) concluded that MRgFUS successfully created a lesion (postoperative lesion >1 mm on MRI) for anterior capsulotomy in 28 of 36 subjects[21,23]. These subjects include patients with MDD or obsessive-compulsive disorder who underwent identical MRgFUS procedures. Unsuccessful lesioning primarily resulted from insufficient temperature elevation within the anterior limb of the internal capsule, under practical and safety considerations such as treatment duration and scalp heating. The key factors affecting maximum temperatures achieved were skull density, skull thickness, and angle of incidence[33]. A lower skull density and increased skull thickness were associated with lower achieved temperature. MRgFUS successfully created lesions in 13 patients with MDD; 5 of 13 met responder criteria (≥50% improvement from baseline on the Hamilton Depression Rating Scale) at 12 months postoperative, and 7 of 13 met responder criteria at 24 months at long-term (follow-up for up to 24 months postoperative). The reductions in Hamilton Depression Rating Scale is 28.13% ± 11.24% at 6 months postoperatively (compared with baseline, $p = 0.027$, $t = 2.520$, $n = 13$, paired t-test), and 22.98% ± 12.65% at 12 months postoperatively (compared with baseline, $p = 0.071$, $t = 1.986$, $n = 13$, paired t-test), and 39.37% ± 19.38 at long-term (compared with baseline, $p = 0.093$, $t = 2.071$, n

= 6, paired t-test). No serious adverse events were reported for all patients undergoing MRgFUS for capsulotomy. Nonserious adverse events included transient headaches lasting for a few hours after MRgFUS, pin-site swelling, and a sensation of fogginess.

Table 2. Summary of findings

LIFUS neuromodulation as a treatment for MDD
Population: patients with major depressive disorder or animal models showing depressive-like behaviors
Intervention: Low-intensity focused ultrasound neuromodulation

Outcome	Compared to	Number of subjects	Estimated effect** (95% CI)	Certainty of the evidence^ (GRADE)[39]	Justification
Randomized clinical trials					
Depression scale score*	Baseline	53	-2.291 (-2.796, -1.785)	Moderate	Downgrade 2 certainty level because of heterogeneity and of imprecision^^, upgrade 1 level for large effects.
	Sham	105	-0.886 (-1.290, -0.482)	Moderate	Downgrade 1 certainty level because of imprecision.
Rodent studies					
Sucrose preference index	Sham	172	1.330 (1.118, 1.541)	Low	Downgrade 1 certainty level because of high heterogeneity, upgrade 1 level because of large effects
Immobility time in the forced swimming test	Sham	192	-0.610 (-0.881, -0.338)	Very low	Downgrade 2 certainty level because of high heterogeneity and imprecision.
Immobility time in the tail suspension test	Sham	123	-1.697 (-2.214, -1.179)	Low	Downgrade 1 certainty level because of high heterogeneity, upgrade 1 level because of large effects

*includes Hamilton Depression Rating Scale and the Montgomery-Åsberg Depression Rating Scale
**measured by Cohen's d
^For preclinical study, the initial certainty level of the evidence starts is low due to risk of bias. For randomized controlled trials, the initial certainty level of the evidence is high.
^^ We downgrade the certainty of evidence due to imprecision if either of the following conditions was met: (1) the optimal information size (OIS) criterion was not fulfilled, assuming the clinical meaningful effect of 0.5 Cohen's d; or (2) the 95% confidence interval for the effect size overlapped with the clinical meaningful effect.



Fig 3. Efficacy of low-intensity focused ultrasound (LIFUS) stimulation in preclinical studies with rodent models. **A-C.** The effect of LIFUS neuromodulation on (**A**) immobility time in forced swimming test (seconds), (**B**) sucrose preference index (a.u.), and (**C**) immobility time in tail suspension test (s). The effect size was estimated using data before and after LIFUS stimulation. Note in Herlihy et al.[32], 2023 (**A**), the immobility time in the forced swimming test was not increased in the depressive rat model compared to healthy rats.



Fig 4. Efficacy of low-intensity focused ultrasound (LIFUS) stimulation in randomized clinical trials. **A.** The effect of LIFUS on depression severity within the treatment group was assessed using depression scale scores before and after LIFUS treatment. **B**. Comparative effect of LIFUS on depression assessment scale compared to sham treatment. Effect size was calculated as the difference in changes in depression severity between the LIFUS treatment and sham control groups.

Efficacy of LIFUS neuromodulation for treating depression

The eight rodent model studies in our review utilized three metrics to assess depressive-like behavior: immobility time in the forced swimming test (reported in 6 of 8 rodent studies), sucrose preference index (reported in 5 of 8 rodent studies), and immobility time in the tail suspension test (reported in 5 of 8 rodent studies). LIFUS had a medium effect (Cohen's d) on reducing immobility time in the forced swimming test ($\bar{d} = -0.610, 95\%CI = [-0.881, -0.338], I^2 = 76.369\%,$ **Figure 3A**). The pooled effect size for the sucrose preference index was large ($\bar{d} = 1.330, 95\%CI = [1.118, 1.541],$ **Figure 3B**). However, there was substantial variability in effect sizes across studies ($I^2 = 83.418\%$). In addition, LIFUS reduced immobility time in the tail suspension test with a large effect ($\bar{d} = -1.697, 95\%CI = [-2.214, -1.179], I^2 = 54.759\%,$ **Figure 3C**). Five out of the eight rodent studies performed H&E staining and confirmed damage or hemorrhage observed in the targeted tissue.

This review evaluated 11 studies in humans, and five of those investigated the effects of LIFUS neuromodulation in patients with MDD. One case study reported that LIFUS neuromodulation targeting the subcallosal cingulate cortex resolved depressive symptoms. The patient's Hamilton Depression Rating Scale-6 score decreased from 11 to 0, and the patient remained in remission during 44 days of monitoring. One study reported that ultrasonic stimulation of the subgenual cingulate cortex immediately reduced depression severity in two patients, as assessed by a psychiatrist. The other three studies reported the results of randomized clinical trials and reported standard depression assessment at baseline and follow-ups for both active stimulation and sham groups. The synthesized response rate is 77.36% (41/53) in the treatment group, compared to 44.23% (23/52) in the sham group (Odd ratio = 4.31). LIFUS had a large effect on reducing depression severity within the ultrasound

treatment group compared to the baseline depression score ($\bar{d} = -2.291, 95\%CI = [-2.796, -1.785]$, $I^2 = 84.5\%$, **Figure 4A**). LIFUS also had a large effect on reducing depression severity in the ultrasound treatment group when compared with the sham control group after adjusting for baseline scores ($\bar{d} = -0.886, 95\%CI = [-1.290, -0.482]$, $I^2 = 33.5\%$ **Figure 4B**). A summary of findings using the GRADE approach to assess the certainty of the evidence is provided in **Table 2**. LIFUS neuromodulation was well tolerated in the three randomized clinical trials, with 3/53 patients in the active treatment group and 4/52 patients in the sham control group reporting dizziness, vomiting, or diarrhea. Two patients experienced severe psychiatric adverse events in the LIFUS neuromodulation group after the 24-hour follow-up time point[37]. Both patients had histories of similar mood swings, and their adverse symptoms resolved within two weeks.

Discussion

This systematic review critically analyzed published studies reporting the use of ultrasound to treat major depressive disorder and depressive-like behaviors in humans and rodent models. The application techniques included magnetic resonance–guided focused ultrasound for anterior capsulotomy and low-intensity transcranial ultrasound for neuromodulation. The current literature suggests the responder rates of 53.85% for MRgFUS capsulotomy and 77.36% for LIFUS neuromodulation, compared to 44.3% for transcranial magnetic stimulation[40], 30–40% for vagus nerve stimulation[41], and 40–70 % for deep brain stimulation[42]. Low-intensity ultrasound had a medium-to-large effect on mitigating depressive-like behaviors in rodent studies, suggesting its promising translation in humans. However, several key challenges need to be resolved to achieve the full potential of ultrasound therapy for MDD in humans.

To date, there are 9 completed or ongoing clinical trials registered on ClinicalTrials.gov that investigate ultrasonic interventions in treating MDD (NCT06085950, NCT05697172, NCT06285474, NCT03421574, NCT06320028, NCT06013384, NCT05301036, NCT04405791, NCT05551585). The limited number of clinical studies and small patient cohorts is a limitation of this review. This highlights the need for larger trials to establish the clinical efficacy and safety profiles of HIFUS and LIFUS for treating depression. A major challenge in development of HIFUS for thermal ablation is its inconsistent success rate. Although MRgFUS is noninvasive and has minimal reported serious adverse effects, it does not consistently achieve successful ablation of the anterior limb of the internal capsule for treating MDD. MRgFUS efficacy in MDD patients with successful lesioning is comparable to that of traditional bilateral anterior capsulotomy, which has a reported success rate of approximately 40%[43]. Anterior capsulotomy is the most effective and safest option for ablative interventions in MDD compared with other targets in ablative surgery, such as bilateral anterior cingulotomy and bilateral subcaudate tractotomy[43]. Therefore, exploring alternative ablative targets for MRgFUS is unlikely to yield substantial improvements in clinical outcomes. Instead, efforts should focus on refining patient selection through neuroimaging or neurophysiological biomarkers that are predictive of treatment response[44]. Key predictors of

successful ablation, including skull density ratio and skull thickness, can be integrated with these biomarker to identify candidates most likely to benefit from ultrasound-based interventions. Furthermore, individualized functional targeting, applied in other brain stimulation techniques such as transcranial magnetic stimulation, may offer a model for tailoring MRgFUS treatments to the unique neurophysiological profiles of individual patient[45].

The application of LIFUS therapy for patients with MDD faces two primary challenges: limited exploration of its parameter space and an incomplete understanding of its underlying mechanisms. All studies included in this review were published after 2017, which may explain the lack of comprehensive investigations into the effects of specific parameters. We anticipate that future research will expand this parameter space, as LIFUS has a medium-to-strong effect on reducing depressive behaviors in animal models and human clinical studies. A further challenge is the lack of rapid and reliable biomarkers of mood. The therapeutic effects of ultrasound in MDD are typically evaluated with outcome measures that unfold over weeks, which limits a systematic and comprehensive exploration of the parameter space. Structural and functional neuroimaging have been investigated as potential ways to obtain shorter-term feedback, although no definitive biomarkers have yet been established[46].

No formal guidelines currently exist to determine the optimal ultrasound stimulation sites for treating depression. Several brain regions and peripheral targets have been explored, and the current literature contains considerable variations in treatment protocols. It would be useful to establish whether a universal stimulation target exists or if individualized approaches will ultimately prove more effective. Despite variations in treatment protocol, LIFUS consistently reduced depressive-like behaviors in rodent studies and mitigated depressive symptoms in human clinical trials. Depression is increasingly conceptualized as arising from dysfunctional connectivity across distributed neural circuits. Directing LIFUS to key nodes within these aberrant networks may disrupt pathological activity and yield therapeutic benefits[47]. This hypothesis warrants further investigation.

The precise mechanisms driving low-intensity ultrasound modulation of neuronal activity have not been established. It will be crucial to determine whether these mechanisms are mediated by thermal, mechanical, or cavitation-based effects, or a combination of these effects, to optimize ultrasound stimulation protocols and align them with established neurobiological pathways of depression. LIFUS has distinct advantages as a noninvasive neuromodulatory technique that penetrates into deep brain tissue. Temporal interference electrical neurostimulation is a potential rival technique that uses multiple high-frequency electric fields to provide steerable and focal stimulation[48]. How small a focal volume may be achieved via temporal interference stimulation remains an open question, but an animal study showed that temporal interference stimulation can activate the mouse hippocampus without stimulating the overlying cortex[49]. In comparison, the focal volume for transcranial FUS is 23 mm^3 under a 0.5 mm mouse skull, a size comparable to the volume of the mouse hippocampus[50]. Although both approaches can noninvasively stimulate subcortical structures, their differing modes of action (electrical vs mechanical) may differentially confer greater efficacy in specific patient populations or disease states Future research should systematically compare the neurophysiological outcomes of ultrasound neuromodulation and

temporal interference across patient populations. These studies may identify disease categories that respond better to mechanical or thermal mechanisms.

Conclusion

Ultrasound applications open exciting new avenues for treating MDD through noninvasive ablation and neuromodulation. HIFUS for anterior capsulotomy had a response rate of 38.46%, which is comparable to traditional capsulotomy with stereotactic surgery. Future development of HIFUS will benefit from refined patient selection and technological advances to ensure consistent lesioning. LIFUS had a response rate of 77.36% in clinical studies. In addition, LIFUS neuromodulation achieved a medium-to-large effect on resolving depressive-like behavior in rodents and reducing depression score in humans. However, the mechanism underlying LIFUS neuromodulation has not been established, and the stimulation parameters have been insufficiently explored. As ultrasound applications continue to evolve, it will be crucial to integrate mechanistic research and refine stimulation protocols to develop a safer and more effective neuromodulation strategy in MDD.

Data availability

Data supporting the findings of this study are available within the article and its supplementary materials. Analysis codes for meta-analysis are available at https://github.com/GanshengT/Meta_analysis_ultrasound/tree/main .

Declaration of Generative AI and AI-assisted technologies in the writing process'

During the preparation of this work, the authors used ChatGPT in order to detect grammatical errors. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Declaration of interests

ECL and HC are inventors on an awarded US patent filed by Washington University in St. Louis on the sonobiopsy technique (US11667975B2), which covers the overall methods and systems for noninvasive and localized brain liquid biopsy using focused ultrasound. ECL and HC serve as advisors and shareholders of Cordance Medical, Inc., which is involved in commercializing the sonobiopsy technique. This relationship did not influence the design, execution, or interpretation of the study presented in this manuscript. The conflict of interest has been rigorously managed by Washington University in St. Louis. ECL received consulting fee from Neurolutions and own stock from Neurolutions, Osteovantage, Face to Face Biometrics, Caeli Vascular, Acera,

Sora Neuroscience, Inner Cosmos, Kinetrix, NeuroDev, Inflexion Vascular, Aurenar, Petal Surgical, which are not related to the present study.

Acknowledgments

This work was supported by the National Institutes of Health R01CA276174. The manuscript was edited by the Scientific Editing Service of the Institute of Clinical and Translational Sciences at Washington University, which is supported by an NIH Clinical and Translational Science Award (UL1 TR002345).

Authorship Statements

All authors designed and conducted the study, including record retrieval, screening, identifying risks of bias and quality assessment. Gansheng Tan extracted and analyzed data and prepared the manuscript draft with important intellectual input from Eric Leuthardt and Hong Chen. All authors reviewed and approved the final version of the manuscript.

Reference

1. Major Depression - National Institute of Mental Health (NIMH). https://www.nimh.nih.gov/health/statistics/major-depression.
2. Artigas, F. Serotonin receptors involved in antidepressant effects. *Pharmacol. Ther.* **137**, 119–131 (2013).
3. Keller, J. *et al.* HPA Axis in Major Depression: Cortisol, Clinical Symptomatology, and Genetic Variation Predict Cognition. *Mol. Psychiatry* **22**, 527–536 (2017).
4. Steger, M. F. & Kashdan, T. B. Depression and Everyday Social Activity, Belonging, and Well-Being. *J. Couns. Psychol.* **56**, 289–300 (2009).
5. Levey, D. F. *et al.* Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat. Neurosci.* **24**, 954–963 (2021).
6. Owens, M. J. & Nemeroff, C. B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. *Clin. Chem.* **40**, 288–295 (1994).
7. Trivedi, M. H. *et al.* Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. *Am. J. Psychiatry* **163**, 28–40 (2006).
8. Voineskos, D., Daskalakis, Z. J. & Blumberger, D. M. Management of Treatment-Resistant Depression: Challenges and Strategies. *Neuropsychiatr. Dis. Treat.* **16**, 221–234 (2020).
9. Davidson, B. *et al.* Magnetic resonance-guided focused ultrasound capsulotomy for refractory obsessive compulsive disorder and major depressive disorder: clinical and imaging results from two phase I trials. *Mol. Psychiatry* **25**, 1946–1957 (2020).

10. S, H., A, F., T, N., T, K. & T, T. Radiofrequency Ablation for Movement Disorders: Risk Factors for Intracerebral Hemorrhage, a Retrospective Analysis. *Oper. Neurosurg. Hagerstown Md* **21**, (2021).
11. Berlim, M. T., Eynde, F. van den, Tovar-Perdomo, S. & Daskalakis, Z. J. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. *Psychol. Med.* **44**, 225–239 (2014).
12. Vidal-Jove, J. *et al.* First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. *Int. J. Hyperthermia* **39**, 1115–1123 (2022).
13. Feng, J. & Li, Z. Progress in Noninvasive Low-Intensity Focused Ultrasound Neuromodulation. *Stroke* **55**, 2547–2557 (2024).
14. Wang, L. *et al.* Ultrasound Stimulation Attenuates CRS-Induced Depressive Behavior by Modulating Dopamine Release in the Prefrontal Cortex. *IEEE Trans. Neural Syst. Rehabil. Eng. Publ. IEEE Eng. Med. Biol. Soc.* **32**, 1314–1323 (2024).
15. Wu, C. *et al.* Ultrasound neuromodulation ameliorates chronic corticosterone-induced depression- and anxiety-like behaviors in mice. *J. Neural Eng.* **20**, 036037 (2023).
16. Hou, X. *et al.* Nanobubble-actuated ultrasound neuromodulation for selectively shaping behavior in mice. *Nat. Commun.* **15**, 2253 (2024).
17. Zhang, J. *et al.* Low-intensity pulsed ultrasound ameliorates depression-like behaviors in a rat model of chronic unpredictable stress. *CNS Neurosci. Ther.* **27**, 233–243 (2021).
18. Yi, S. *et al.* Ultrasound Stimulation of Prefrontal Cortex Improves Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice. *Front. Psychiatry* **13**, (2022).
19. Zhu, Y. *et al.* Transcranial ultrasound stimulation relieves depression in mice with chronic restraint stress. *J. Neural Eng.* **20**, (2023).
20. Zhang, D. *et al.* Antidepressant-Like Effect of Low-Intensity Transcranial Ultrasound Stimulation. *IEEE Trans. Biomed. Eng.* **66**, 411–420 (2019).
21. Kim, M., Kim, C.-H., Jung, H. H., Kim, S. J. & Chang, J. W. Treatment of Major Depressive Disorder via Magnetic Resonance–Guided Focused Ultrasound Surgery. *Biol. Psychiatry* **83**, e17–e18 (2018).
22. Oh, J. *et al.* Effect of Low-Intensity Transcranial Focused Ultrasound Stimulation in Patients With Major Depressive Disorder: A Randomized, Double-Blind, Sham-Controlled Clinical Trial. *Psychiatry Investig.* **21**, 885–896 (2024).
23. Hamani, C. *et al.* Long-term safety and efficacy of focused ultrasound capsulotomy for obsessive-compulsive disorder and major depressive disorder. *Biol. Psychiatry* S0006-3223(24)01548–8 (2024) doi:10.1016/j.biopsych.2024.08.015.
24. Page, M. J. *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* **372**, n71 (2021).
25. Sterne, J. A. C. *et al.* RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* **366**, l4898 (2019).

26. Higgins, J. P. T. *et al.* A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). *Environ. Int.* **186**, 108602 (2024).

27. Hooijmans, C. R. *et al.* SYRCLE's risk of bias tool for animal studies. *BMC Med. Res. Methodol.* **14**, 43 (2014).

28. Hedges, L. V. Distribution Theory for Glass's Estimator of Effect Size and Related Estimators. *J. Educ. Stat.* **6**, 107–128 (1981).

29. 9.5.2 Identifying and measuring heterogeneity. https://handbook-5-1.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm.

30. Riis, T., Feldman, D., Losser, A., Mickey, B. & Kubanek, J. Device for Multifocal Delivery of Ultrasound Into Deep Brain Regions in Humans. *IEEE Trans. Biomed. Eng.* **71**, 660–668 (2024).

31. Riis, T. S. *et al.* Durable effects of deep brain ultrasonic neuromodulation on major depression: a case report. *J. Med. Case Reports* **17**, 449 (2023).

32. Herlihy, R. A. *et al.* Investigation of non-invasive focused ultrasound efficacy on depressive-like behavior in hemiparkinsonian rats. *Exp. Brain Res.* **242**, 321–336 (2024).

33. Davidson, B. *et al.* Technical and radiographic considerations for magnetic resonance imaging-guided focused ultrasound capsulotomy. *J. Neurosurg.* **135**, 291–299 (2021).

34. Davidson, B. *et al.* Examining cognitive change in magnetic resonance-guided focused ultrasound capsulotomy for psychiatric illness. *Transl. Psychiatry* **10**, 397 (2020).

35. Davidson, B. *et al.* Magnetic Resonance-Guided Focused Ultrasound Capsulotomy for Treatment-Resistant Psychiatric Disorders. *Oper. Neurosurg.* **19**, 741 (2020).

36. Li, X., Weng, F., Sun, W., Liu, R. & Xu, H. Preliminary Research on Depression Treatment: Combination of Transcranial Magnetic Stimulation and MRI-Guided Low-Intensity Focused Ultrasound Pulsation. *J. Med. Imaging Health Inform.* **10**, 677–680 (2020).

37. Riis, T. S. *et al.* Noninvasive Modulation of the Subcallosal Cingulate and Depression With Focused Ultrasonic Waves. *Biol. Psychiatry* **0**, (2024).

38. Ram, Z. *et al.* Magnetic resonance imaging-guided, high-intensity focused ultrasound for brain tumor therapy. *Neurosurgery* **59**, 949–955; discussion 955-956 (2006).

39. CDC. Chapter 7: GRADE Criteria Determining Certainty of Evidence. *ACIP GRADE Handbook for Developing Evidence-based Recommendations* https://www.cdc.gov/acip-grade-handbook/hcp/chapter-7-grade-criteria-determining-certainty-of-evidence/index.html (2024).

40. Vida, R. G. *et al.* Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures: meta-analysis of randomized sham-controlled trials. *BMC Psychiatry* **23**, 545 (2023).

41. Sackeim, H. A. *et al.* Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome. *Neuropsychopharmacology* **25**, 713–728 (2001).

42. Morishita, T., Fayad, S. M., Higuchi, M., Nestor, K. A. & Foote, K. D. Deep Brain Stimulation for Treatment-resistant Depression: Systematic Review of Clinical Outcomes. *Neurotherapeutics* **11**, 475–484 (2014).

43. Hurwitz, T. A., Honey, C. R. & Sepehry, A. A. Ablation Surgeries for Treatment-Resistant Depression: A Meta-Analysis and Systematic Review of Reported Case Series. *Stereotact. Funct. Neurosurg.* **100**, 300–313 (2023).

44. Hacimusalar, Y. & Eşel, E. Suggested Biomarkers for Major Depressive Disorder. *Arch. Neuropsychiatry* **55**, 280–290 (2018).

45. Vila-Rodriguez, F. & Frangou, S. Individualized functional targeting for rTMS: A powerful idea whose time has come? *Hum. Brain Mapp.* **42**, 4079–4080 (2021).

46. Kennis, M. *et al.* Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. *Mol. Psychiatry* **25**, 321–338 (2020).

47. Li, B. *et al.* A brain network model for depression: From symptom understanding to disease intervention. *CNS Neurosci. Ther.* **24**, 1004–1019 (2018).

48. Violante, I. R. *et al.* Non-invasive temporal interference electrical stimulation of the human hippocampus. *Nat. Neurosci.* **26**, 1994–2004 (2023).

49. Grossman, N. *et al.* Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. *Cell* **169**, 1029-1041.e16 (2017).

50. Li, Z. *et al.* Cross-Species Characterization of Transcranial Ultrasound Propagation. *Brain Stimulat.* (2025) doi:10.1016/j.brs.2025.01.007.

Supporting information

Supplementary Figure 1 Quality assessment.



Appendix 1 – Quality Assessment

Quality assessment of studies examining the technique and efficacy of therapeutic ultrasound in the treatment of major depressive disorder

The maximum score for a study is 1 for the Selection, Comparability, and Outcome categories.

Selection

1) Representativeness of the exposed cohort

1: The study includes both genders, and the sample size is> 7. If the study used an animal model, the model should be a valid depression animal model.

0.5 (somewhat representative): Sample size ≥ 5

0: case report

Comparability

1) Comparability of cohorts in study design and statistical analysis

1: The study includes both a treatment group and a control group. The outcome measures for both groups are adjusted for baseline measurement.

0.5: The study outcomes before and after ultrasonic treatment for the treatment group are available. Alternatively, the study includes outcome measures for the treatment group and the control group.

0: The outcome measures before and after treatment are not comparable, for example, due to different measures used.

Outcome

1) Outcome measure

1: standard measures or rating scales for depression that have been validated

0.5: the study includes neuroimaging outcomes, biochemical outcomes, electrophysiological outcomes, or other outcomes that are related to standard rating scales for depression

0: Subjective report

Thresholds for converting the Quality assessment to AHRQ standards (good, moderate, and poor):

Good quality: at least one score for any two of the three categories and at least 0.5 score for the other category

Moderate quality: studies that are neither of good quality nor poor quality.

Poor quality: 0 score for any one of the three categories.